This message was conveyed to Chief Secretary Somesh Kumar who held a meeting with Dr. Krishna Ella, MD, Bharat Biotech on Tuesday at BRKR Bhavan following directions from Chief Minister K. Chandrashekar Rao.
Safety and efficacy results from the final analysis will be available in June and the final report will be submitted to a peer-reviewed publication, says Bharat Biotech
Hyderabad-based vaccine maker implements expansion across multiple facilities in Hyderabad and Bengaluru to reach about 700 million doses per year capacity
Soon after the outbreak, the industry quickly adapted to the supply chain needs and manpower scenario and got into making generic drugs and vaccine development.
The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement.
Life sciences sector in Telangana attracted investments to the tune of about Rs 3,700 crores in last one year with an employment potential for around 14,000 people
Dr Krishna M Ella, CMD and Suchitra Ella, joint managing director, Bharat Biotech International will receive the award on February 22, during the inaugural event of BioAsia 2021.
Under the terms of the agreement, Ocugen will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including emergency use authorisation (EUA)) and commercialisation for the US market.